The latest market report published by Credence Research, Inc. “Nitric Oxide Therapy Systems Market – Growth, Future Prospects, Competitive Analysis, 2018 – 2026,” the global nitric oxide therapy systems market is expected to expand at a CAGR of 5.19 % from 2018 to 2026.
Nitric oxide is produced in the human body by an enzymatic reaction of nitric oxide synthase on L-arginine. Constitutive nitric oxide synthase and inducible nitric oxide synthase are 2 varieties formed in the human body. The deficiency of NOS causes pulmonary diseases such as neonate pulmonary hypertension and acute respiratory distress syndrome. Manufacturers are actively engaged in providing nitric oxide inhalation devices to overcome the complications of pulmonary ailments. INOpulse (Bellerophon Therapeutics) is automatically adjusted in accordance with the patients breathing pattern in order to deliver constant flow of nitric oxide at a fixed dose. Triple lumen nasal cannula is also provided to deliver accurate dose of nitric oxide to the ailing patient. maniNO (EKU Elektronik GmbH) provides blend of oxygen and nitric oxide with high precision and is applicable as manual ventilation, ambulatory services and MRI environment. The dosing capacity is from 0 ppm to 40 ppm and adjustable flow of 0 l/min to15 l/min.
Browse Here for Full Report at https://goo.gl/43xej9
Get Free Sample Request: https://goo.gl/eu23Dj
Durability and lightweight are the meritorious features that increase the demand for portable nitric oxide therapy systems. Relatively low cost, versatility and easy fabrication of the auxiliary holding devices with the main ventilation unit makes fixed nitric oxide therapy systems a lucrative option in the ambulatory care and hospitals.
Hospitals and clinics widely utilize the nitric oxide inhalation therapy in the neonate and intensive care unit to address ailments related to pulmonary disorders and increasing demand for pediatric cardiopulmonary bypass surgery procedures for treating cardiopulmonary ailments. Homecare settings finds huge application of nitric oxide therapy systems for the rehabilitation of geriatric patients suffering with acute respiratory distress syndrome.
North America is the market leader in nitric oxide therapy systems due to the rising prevalence of acute respiratory distress syndrome in the adult population and the presence of key players actively engaged in the manufacturing of nitric oxide therapy systems. Asia Pacific will dominate the market in the near future on account of the rising prevalence of neonate pulmonary hypertension. Competitive market formed due to the emergence of local providers of nitric oxide therapy systems contribute to the growth of Asia Pacific market.
The manufacturers spearheading in the production of nitric oxide therapy systems are Bellerophon Therapeutics, BOC Healthcare, Dan Hammer Health Ltd., EKU Elektronik GmbH, GeNO LLC, International Biomedical, SLE, Mallinckrodt Pharmaceuticals, Praxair, Inc. and Vapotherm.
Key Market Movements:
- Rising prevalence of neonatal pulmonary hypertension and acute respiratory distress syndrome
- Recent technical advancements in the manufacturing of nitric oxide therapy systems will contribute to its market growth
- Supportive regulatory environment for nitric oxide therapy systems
- Portable Nitric Oxide Therapy Systems
- Fixed Nitric Oxide Therapy Systems
By End User
- Homecare Settings
- North America (Canada & United States)
- Europe (Germany, U.K., and Rest of Europe)
- Asia Pacific (Japan, China, India and Rest of Asia Pacific)
- Latin America (Mexico, Brazil, and Rest of Latin America)
- Middle East and Africa (GCC and Rest of Middle East and Africa)